Clinical Trial Update: A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating palbociclib with exemestane and GnRH versus capecitabine in premenopausal women with HR+ metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Exemestane (Exemestane)
• GnRH (gonadotropin-releasing hormone)
• Palbociclib (palbociclib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN